- |||||||||| Visken (pindolol) / Novartis
Journal: Pindolol Use for Treatment-Refractory Panic Disorder. (Pubmed Central) - Dec 6, 2024
Data from this bridging study of enantiomerically pure ACM-001.1 and its parent racemic drug, pindolol, support clinical trials of ACM-001.1 for the treatment of cancer cachexia. No abstract available
- |||||||||| Visken (pindolol) / Novartis
Journal, Machine learning: Machine learning in obsessive-compulsive disorder medications. (Pubmed Central) - Nov 25, 2024
The ML analysis provided valuable insights into the efficacy of various medications such as clomipramine, duloxetine, and pindolol, as well as supplements such as folate, in the treatment of OCD. Treating concomitant diseases, namely hypothyroidism and streptococcal infection could improve the efficacy of treatment.
- |||||||||| Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
Enrollment change: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Oct 16, 2024
P2, N=47, Completed,
Treating concomitant diseases, namely hypothyroidism and streptococcal infection could improve the efficacy of treatment. N=80 --> 47
- |||||||||| Visken (pindolol) / Novartis
Journal: Magnetic particle spray mass spectrometry for the determination (Pubmed Central) - Sep 25, 2024
The method is aligned with green chemistry principles, requiring minimal sample, solvent, and sorbent amounts. MPS-MS successfully integrates sample preparation and ambient ionization mass spectrometry and holds great potential for application with other sorbents, samples, and analytes.
- |||||||||| Visken (pindolol) / Novartis
BATTLING BETA BLOCKER OVERDOSE: A RACE AGAINST TIME FOLLOWING METOPROLOL OVERDOSE (Convention Center Exhibit Hall: Poster Area 2) - Sep 11, 2024 - Abstract #CHEST2024CHEST_6365;
Beta- Blockers such as Metoprolol overdose, presents a challenging clinical scenario requiring prompt recognition and aggressive management. Early initiation of supportive measures, including intravenous fluids, vasopressors, and calcium gluconate, along with gastrointestinal decontamination, can significantly reduce morbidity and mortality associated with metoprolol toxicity.
- |||||||||| Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Jun 13, 2024
P2, N=80, Completed,
The applicability of our method was demonstrated by the analysis of two authentic human autopsy blood samples. Recruiting --> Completed | N=134 --> 80 | Trial completion date: Feb 2025 --> Jun 2024
- |||||||||| Review, Journal: Drugs for hypertension. (Pubmed Central) - May 21, 2024
Recruiting --> Completed | N=134 --> 80 | Trial completion date: Feb 2025 --> Jun 2024 No abstract available
- |||||||||| Visken (pindolol) / Novartis
Preclinical, Journal: Evaluation of multitarget drugs on the expression of cocaine-induced locomotor sensitization in male rats: A comparative study. (Pubmed Central) - May 10, 2024
No abstract available Here we compare the efficacy of mirtazapine (MIR), pindolol (PIN), fluoxetine (FLX), risperidone (RIS), trazodone (TRZ), ziprasidone (ZPR), ondansetron (OND), yohimbine (YOH), or prazosin (PRZ), to reduce long-term cocaine-induced locomotor activity and the expression of cocaine-induced locomotor sensitization in rats...After each administration, locomotor activity for each animal was recorded for 30
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Journal: Electrochemical screening of selected ?-blockers at a polarized liquid-liquid interface. (Pubmed Central) - Mar 8, 2024
The latter were compared and correlated with the available literature values of log?Poctanol. Finally, a standard addition method was used to determine the concentration of nebivolol in pharmaceutical preparations using a platform based on the electrified liquid-liquid interface.
- |||||||||| Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Feb 19, 2024
P2, N=134, Recruiting,
Finally, a standard addition method was used to determine the concentration of nebivolol in pharmaceutical preparations using a platform based on the electrified liquid-liquid interface. Trial primary completion date: Feb 2024 --> Feb 2025
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial completion, Enrollment change, Trial completion date: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Jul 3, 2023
P4, N=9, Completed,
This is the basis for the pharmacological concept of "functional affinity". Recruiting --> Completed | N=16 --> 9 | Trial completion date: Sep 2023 --> Apr 2023
- |||||||||| Visken (pindolol) / Novartis
Preclinical, Journal: Effects of S-pindolol in mouse pancreatic and lung cancer cachexia models. (Pubmed Central) - Jun 5, 2023
S-pindolol is an important candidate for clinical development in the treatment of cancer cachexia that strongly attenuates loss of body weight and lean body mass. This was also seen in the weight of individual muscles and resulted in higher grip strength.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial completion, Trial completion date, Trial primary completion date: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - May 11, 2023
P4, N=9, Completed,
This was also seen in the weight of individual muscles and resulted in higher grip strength. Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Apr 2023 | Trial primary completion date: Oct 2023 --> Apr 2023
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment closed, Enrollment change, Trial primary completion date: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Mar 1, 2023
P4, N=9, Active, not recruiting,
Active, not recruiting --> Completed | Trial completion date: Oct 2023 --> Apr 2023 | Trial primary completion date: Oct 2023 --> Apr 2023 Recruiting --> Active, not recruiting | N=16 --> 9 | Trial primary completion date: Dec 2022 --> Oct 2023
- |||||||||| Visken (pindolol) / Novartis
Potential of Arachis hypogaea testa as a functional food ingredient for the treatment of depression (Pennsylvania Station B/C (Crown Plaza Indianapolis Downtown Union Square)) - Feb 14, 2023 - Abstract #ACSSp2023ACS_SP_3544;
Pindolol (10 mg/kg), a 5HT1A receptor antagonist, reversed the antidepressant effects of C9-C3, an efficacious medium polarity fraction (p < 0.001)...Lead was detected in the testa at 4.88 ppm and a qualitative pesticide screening detected the presence of chlorflurenol and o-hydroxybiphenyl. This study confirms that Arachis hypogaea testa has the potential for commercial value as a functional food ingredient for the treatment of depression; however, heavy metals, biocides and pesticides are a food safety concern.
- |||||||||| Edsivo (celiprolol) / Acer Therap, Visken (pindolol) / Novartis, bevantolol (SOM3355) / SOM Biotech
Journal: β-arrestin2 recruitment by β-adrenergic receptor agonists and antagonists (Pubmed Central) - Jan 4, 2023
β2-AR selective antagonists butoxamine showed β-arrestin2 recruitment at β1-AR. These results provide some clues for the potential action of β-AR drugs, and lay a foundation for the screening of β-arrestin-biased β-AR ligands.
- |||||||||| S-oxprenolol (ACM-002) / Actimed Therap
Preclinical, Journal: The atypical β-blocker S-oxprenolol reduces cachexia and improves survival in a rat cancer cachexia model. (Pubmed Central) - Nov 9, 2022
The performance of the adsorbent was further evaluated using environmental waters and the adsorbent demonstrated good potential for simultaneous adsorption of multicomponent pharmaceuticals. S-oxprenolol is superior to R-oxprenolol in cancer cachexia animal models and shows promise for a human application in cancer cachexia.
- |||||||||| Visken (pindolol) / Novartis, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: Study of Human Non-Shivering Thermogenesis and Basal Metabolic Rate (clinicaltrials.gov) - Aug 22, 2022
P2, N=134, Recruiting,
The synthetic method can serve for the preparation of a broad scope of enantiomerically enriched β-blockers, the chemical structures of which rely on the common α-hydroxy-N-isopropylamine moiety, and in this sense, might be industrially attractive. Trial completion date: Feb 2023 --> Feb 2025 | Trial primary completion date: Feb 2023 --> Feb 2024
- |||||||||| Visken (pindolol) / Novartis, dizocilpine (MK801) / Merck (MSD)
Preclinical, Journal: Mechanistic pathways of fibromyalgia induced by intermittent cold stress in mice is sex-dependently. (Pubmed Central) - Aug 11, 2022
Except L-arginine, MK-801 and methylene blue also attenuated this nociceptive signal in male mice, after ICS exposure. In conclusion, the modulation of serotonergic receptors, the NMDA/NO/cGMP pathway, and the oxidative stress seems contribute to nociceptive behaviors induced by ICS exposure sex-dependent.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial primary completion date: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Jun 28, 2022
P4, N=16, Recruiting,
The results demonstrate that β- and β-/β-adrenoceptor receptor antagonists act as 6-ND receptor antagonists in RIEVD, further confirming the main role of 6-ND in the RIEVD contractility. Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Trial primary completion date: Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF (clinicaltrials.gov) - Jun 28, 2022
P4, N=16, Recruiting,
Trial primary completion date: Sep 2022 --> Dec 2022 Trial primary completion date: Sep 2022 --> Dec 2022
- |||||||||| Visken (pindolol) / Novartis, Mikelan (carteolol) / Senju
Journal: Preparation and Evaluation of an Azobenzenediamide Bridged bis(β-Cyclodextrin)-Bonded Chiral Stationary Phase for HPLC. (Pubmed Central) - Jun 22, 2022
For example, it could resolve myclobutanil, pindolol, carteolol, betaxolol, bevanolol and bitertanol, which could not be resolved before, and should be related to the fact that the flexible N=N was more compatible with the synergistic inclusion between cavities than the rigid C=C bridge group. The azobenzenediamide bridging group could also provide hydrogen bond, π-π and other sites, which was conducive to chiral separations.
- |||||||||| Visken (pindolol) / Novartis, Bystolic (nebivolol) / Menarini, AbbVie
Enrollment status: Impact of Beta-blockers on Physical Function in HFpEF (clinicaltrials.gov) - Apr 28, 2022
P4, N=16, Recruiting,
These anxiolytic-like effects seem to involve the HPA axis and 5-HT systems. Enrolling by invitation --> Recruiting
- |||||||||| Visken (pindolol) / Novartis
Journal: Molecular Imprinting Using a Functional Chain Transfer Agent. (Pubmed Central) - Feb 26, 2022
Selectivity studies, cross-reactivity as well as binary competitive and displacement assays showed the TGA-based MIPs to be highly selective towards PNL against pindolol and slightly competitive against atenolol. The morphologies of the polymers were shown to be affected by the concentration of the TGA, transforming into discrete macrospheres (from small aggregates) at a higher TGA concentration.
- |||||||||| Visken (pindolol) / Novartis
Clinical, PK/PD data, Journal: β-adrenoceptor antagonists and nightmares: A pharmacoepidemiological-pharmacodynamic study. (Pubmed Central) - Feb 22, 2022
Use of moderate or high 5-HT affinity of β-adrenoceptor antagonists was associated with an increased ROR of nightmares compared with low 5-HT affinity of β-adrenoceptor antagonists (aROR moderate vs. low 1.22, 95%CI 1.04-1.43 and aROR high vs. low 2.46, 95%CI 1.93-3.13). In our large pharmacovigilance study, nightmares are more frequently reported for pindolol and metoprolol, and among β-adrenoceptor antagonists with high lipid solubility and high 5-HT receptor affinity.
- |||||||||| Ciprol (ciprofibrate) / Sanofi, Cetaxin (ciprofibrat) / AC Farma, Visken (pindolol) / Novartis
Biomarker, Journal: Precision medicine for mood disorders: objective assessment, risk prediction, pharmacogenomics, and repurposed drugs. (Pubmed Central) - Jan 27, 2022
Finally, we provide an example of how a report to doctors would look for a patient with depression, based on the panel of top biomarkers (12 for depression and bipolar, one for mania), with an objective depression score, risk for future depression, and risk for bipolar switching, as well as personalized lists of targeted prioritized existing psychiatric medications and new potential medications. Overall, our studies provide objective assessments, targeted therapeutics, and monitoring of response to treatment, that enable precision medicine for mood disorders.
- |||||||||| Rexulti (brexpiprazole) / Lundbeck, Otsuka, Metopirone (metyrapone) / HRA Pharma
Review, Journal: Augmentative Pharmacological Strategies in Treatment-Resistant Major Depression: A Comprehensive Review. (Pubmed Central) - Jan 7, 2022
Studies on lamotrigine and pindolol reported negative results...Reliable conclusions about the other molecules cannot be drawn. Further controlled comparative studies, standardized in terms of design, doses, and duration of the augmentative treatments, are needed to formulate definitive conclusions.
|
